Charles Schwab
RXII

Charles Schwab’s GALENA BIOPHARMA INC COM RXII Stock Holding History

Charles Schwab’s Portfolio RXII Stock Details RXII Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-265,000
Closed -$93K – 3111
2016
Q3 		$93K Hold
265,000
– – ﹤0.01% 3017
2016
Q2 		$124K Hold
265,000
– – ﹤0.01% 3038
2016
Q1 		$361K Hold
265,000
– – ﹤0.01% 2714
2015
Q4 		$390K Buy
265,000
+75,300
+40% +$111K ﹤0.01% 2756
2015
Q3 		$300K Hold
189,700
– – ﹤0.01% 2829
2015
Q2 		$323K Hold
189,700
– – ﹤0.01% 2843
2015
Q1 		$264K Hold
189,700
– – ﹤0.01% 2882
2014
Q4 		$287K Hold
189,700
– – ﹤0.01% 2860
2014
Q3 		$391K Hold
189,700
– – ﹤0.01% 2676
2014
Q2 		$581K Buy
189,700
+42,400
+29% +$130K ﹤0.01% 2561
2014
Q1 		$369K Hold
147,300
– – ﹤0.01% 2715
2013
Q4 		$731K Buy
147,300
+28,300
+24% +$140K ﹤0.01% 2424
2013
Q3 		$269K Hold
119,000
– – ﹤0.01% 2801
2013
Q2 		$263K Buy
+119,000
New +$263K ﹤0.01% 2783

Charles Schwab's RXII Position: Q4 2016 in Review

Charles Schwab sold out of GALENA BIOPHARMA INC COM (RXII) in Q4 2016, closing a stake of 265,000 shares — an estimated $93K sold.

Charles Schwab first reported a position in RXII in Q2 2013 and held it in 14 quarters. The position peaked at $731K in Q4 2013. 0 funds tracked by Wall St. Rank hold RXII as of Q4 2016.

  • Charles Schwab reported no remaining GALENA BIOPHARMA INC COM position as of Q4 2016 after selling out during the quarter.
  • Charles Schwab sold 265,000 GALENA BIOPHARMA INC COM shares in Q4 2016, an estimated $93K.
  • Charles Schwab first reported a position in GALENA BIOPHARMA INC COM in Q2 2013 and held it in 14 quarters.
  • Charles Schwab's GALENA BIOPHARMA INC COM position peaked at $731K in Q4 2013.
  • 0 funds tracked by Wall St. Rank held GALENA BIOPHARMA INC COM as of Q4 2016.

Based on Charles Schwab's 13F filing for Q4 2016, filed 13 Feb 2017.